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Background: Ginsenoside F1, a pharmaceutical component of ginseng, is known to have antiaging,
antioxidant, anticancer, and keratinocyte protective effects. However, the usage of ginsenoside F1 is
restricted owing to the small amount found in Korean ginseng.
Methods: To enhance the production of ginsenoside F1 as a 10 g unit with high speciﬁcity, yield, and
purity, an enzymatic bioconversion method was developed to adopt the commercial enzyme Cellulase
KN from Aspergillus niger with food grade, which has ginsenoside-transforming ability. The proposed
optimum reaction conditions of Cellulase KN were pH 5.0 and 50C.
Results: Cellulase KN could effectively transform the ginsenosides Re and Rg1 into F1. A scaled-up
biotransformation reaction was performed in a 10 L jar fermenter at pH 5.0 and 50C for 48 h with
protopanaxatriol-type ginsenoside mixture (at a concentration of 10 mg/mL) from ginseng roots. Finally,
13.0 g of F1 was produced from 50 g of protopanaxatriol-type ginsenoside mixture with 91.5  1.1%
chromatographic purity.
Conclusion: The results suggest that this enzymatic method could be exploited usefully for the prepa-
ration of ginsenoside F1 to be used in cosmetic, functional food, and pharmaceutical industries.
Copyright 2015, The Korean Society of Ginseng, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ginseng, a well-known medicinal plant, has not only been
used as a traditional medicine in East Asia for thousands of years,
but has also gained recognition in the past decade in the West for
its beneﬁcial uses [1e3]. Many previous reports have shown that
ginseng has extensive pharmacological and therapeutic utility.
Ginsenosides, the major components of ginseng, appear to be
responsible for the principal biological and pharmacological ac-
tivities underpinning anticancer, antitumor, antiallergic, anti-
inﬂammatory, and antioxidant effects [4e10]. Based on the
structure of the aglycon and the dammarane skeleton, ginseno-
sides can be categorized as protopanaxadiol, protopanaxatriol
(PPT), and oleanane saponins [11]. The PPT-type ginsenosides are
further identiﬁed by the number of sugar moieties and the po-
sition of a glycosidic bond at the aglycon C6 and C20. After oralgy, Hankyong National University
alian Polytechnic University, Qing
ra@hknu.ac.kr (W.-T. Im).
orean Society of Ginseng, Publisheintake of ginseng, the major ginsenosides are hydrolyzed into the
more active minor ginsenosides through human intestinal
digestion, and are further absorbed into the blood. Therefore,
conversion of the major ginsenosides, which account for > 80%
of the total ginsenosides, to the highly active minor ginsenosides
may have a signiﬁcant impact on the pharmaceutical industry
[4,5].
The minor ginsenoside F1 is present in low concentrations in
Korean ginseng. It can be processed through deglycosylation by
intestinal microﬂora from the major ginsenosides Re and Rg1; it is
absorbed into the blood, where it exerts an estrogenic effect [12].
Ginsenoside F1 exhibited anticancer effect, showing strong sup-
pression of B16 cell proliferation [13]. Furthermore, ginsenoside F1
shows antiaging and antioxidant effects, and exhibits competitive
inhibition of the activity of CYP3A4 and weaker inhibition of the
activity of CYP2D6 [14,15]., 327 Chungang-no Anseong, Kyonggi, 456-749, Korea.
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enzymatic processes. One example is Fusarium moniliforme var.
sublutinas, which has b-glucosidase activity and has shown the
ability to convert ginsenoside Rg1 into F1 [16]. Another example is
commercially available naringinase from Penicillium decumbens
[17], which has the ability to hydrolyze glucose and the rhamnose
moieties at the C6 position to produce ginsenoside F1 from Re and
Rg1. However, in that study, the researchers conducted only a
simple enzyme presentation, without further scale-up or process
engineering. Although several PPT-type ginsenoside-hydrolyzing
recombinant enzymes have been constructed [18e22], the majority
of these have the ability to hydrolyze the glucose moiety at the C20
position of aglycon to produce Rg2(S) or Rh1(S) from Re or Rg1,
respectively, rather than the glucose moiety at the C6 position of
aglycon. Among these, two enzymes were reported to have hy-
drolyzing activity for the glucose moiety at the C6 position of PPT
aglycon to produce ginsenoside F1 [19,21]. However, the re-
searchers conducted only a simple enzyme characterization,
without further scale-up or process engineering.
The experiment in this study was designed to overcome the
above disadvantages and meet the industrial demand for mass
production of ginsenoside F1 as a food-grade health supplement.
From several commercial enzymes capable of transforming ginse-
nosides, we selected Cellulase KN on the basis of its high activity for
transforming ginsenosides Re and Rg1 into ginsenoside F1. Treat-
ment of a PPT-type ginsenoside mixture (PPTGM) composed of Re
and Rg1 mainly with Cellulase KN followed by puriﬁcation yielded
10 gram-scale F1 with high purity. This is the ﬁrst report of 10 g-
scale production of high-purity F1 by the application of commercial
enzymes to a crude substrate.
2. Materials and methods
2.1. Materials
Standard-grade ginsenosides, including Rg1, Re, Rh1(S), F1, and
PPT, were purchased from Nanjing Zelang Medical Technology Co.,
Ltd (Nanjing, China). The PPTGMwas extracted from the dried roots
of 4 kg of Panax ginseng Meyer together with 1 kg of Panax quin-
quefolius. Five kilograms of ginseng root powder was extractedwith
50 L of 70% ethanol twice. The extract was ﬁltered through ﬁlter
papers and then dried using a rotary evaporator. The resultant dried
powder was dissolved in water and loaded onto a glass column
(400 mm L  100 mm D) packed with Diaion HP-20 resin (Tokyo,
Mitsubishi Chemical). Free sugar molecules and unwanted hydro-
philic compounds from HP-20 absorbed beads were washed with 8
column volumes of water, and ﬁnally PPT-type ginsenosides were
eluted by 8 column volumes of 36% ethanol. The ethanol extracts
were evaporated in vacuo, and the dried residue was used as the
substrate ginsenoside for F1 production. According to the HPLC
analysis, the PPTGM was mainly composed of Re (245 mg/g), Rg1
(203 mg/g), Rb1 (32 mg/g), Rb2, (25 mg/g), Rb3 (53 mg/g), Rd
(80 mg/g), and small amounts of other ginsenosides, and was dis-
solved in 50mMacetate buffer, which could solubilize the PPTGM at
up to 100 mg/mL [19]. HPLC-grade methanol and acetonitrile were
obtained from SK Chemical Co., Ltd (Seoul, Korea). The other
chemicals used in this study were of analytical grade or better.
2.2. Screening of commercial enzymes that can transform PPT-type
ginsenosides
The PPTGMwas diluted in 500 mL of acetate buffer (pH 5.0) as 1%
(w/v) and the same volumes of commercial enzymesdNovozym
960 (Bagsvaerd, Novozyme), Viscozyme (Novozyme), Pectinex
AFPL-4 (Novozyme), Pectinex Ultra SP-L (Novozyme), Fungamyl800L (Novozyme), and Cellulase KN (0.2 g/mL, Kagawa, Kyowa
Chemical)dto be mixed for subsequent testing. The mixture was
shaken aerobically at 150 rpm and 50C for 48 h. The reactants were
taken at regular intervals and analyzed via TLC or HPLC after pre-
treatment (see “Analytic methods” section).
2.3. Biotransformation activity of PPT-type ginsenosides using
Cellulase KN
The activity of Cellulase KN was examined to determine the
speciﬁcity and selectivity of conversion of ginsenosides Re and Rg1
through hydrolysis of the rhamnose and glucose moieties attached
at the C6 position. Enzyme solutions at a concentration of 100 mg/
mL in 100mM acetate buffer (pH 5.0) were reacted with an equal
volume of Re and Rg1 solution at a concentration of 1 mg/mL in
100mM acetate buffer (pH 5.0) at 50C. The samples were taken at
regular intervals and analyzed via TLC or HPLC after pretreatment
(see “Analytic methods” section).
2.4. Biotransformation optimization based on concentration of the
enzyme and substrate
In order to determine the optimal conditions for biotransfor-
mation of the PPTGM using Cellulase KN, the substrate concen-
tration of PPTGM in the reaction was optimized. The ﬁnal enzyme
concentration was ﬁxed at 50 mg/mL and 100 mg/mL and reacted
with the PPTGM dissolved in acetate buffer solution (pH 5.0), in
order to obtain the ﬁnal substrate concentrations of 5 mg/mL,
10 mg/mL, and 15 mg/mL. The six optimization reactions were
performed in a 2 mL Eppendorf tube with a 1 mL working volume
at 200 rpm for 48 h at 50C. The samples were taken at regular
intervals and analyzed via TLC and HPLC.
2.5. Scaled-up biotransformation of PPTGM using Cellulase KN
The scaled-up biotransformation was performed in a 10 L
stirred-tank reactor (Biotron GX; Hanil Science Co. Ltd, Seoul,
Korea) with a 5 L working volume at 200 rpm for 48 hours. The
reaction was performed under pH 5.0 at 50C. The reaction started
with a composition of 10 mg/mL of substrate ginsenoside (PPTGM;
total 50 g) as the ﬁnal concentration, and 500 g of Cellulase KN was
added. Samples were collected at regular intervals and analyzed by
HPLC in order to determine the production of ginsenoside F1 from
the PPTGM.
2.6. Puriﬁcation of F1
Following the 5 L reaction of the PPTGM with Cellulase KN, the
mixture was cooled at 4C and centrifuged at 4,000 rpm for 20 min
(Component R; Hanil Science Co. Ltd). The biotransformed ginse-
noside F1 in the supernatant and precipitate was processed sepa-
rately in order to remove the enzymes, salt, and free sugars from
the reaction mixture. Ginsenoside F1 in the supernatant was pu-
riﬁed using a Biotage SNAP ﬂash chromatography cartridge
(180  70 4 mm; Biotage, Uppsala, Sweden) packed with 340 g of
octadecylsilane (ODS; ZEOprep 60 C18, 40e63 mm), based on
gradient concentration elution with methanol. The precipitate was
also dissolved in 3.0 L of 95% ethanol solution twice and ﬁltered
through a ﬁlter paper (Advantec, Tokyo, Japan) and evaporated in
vacuo.
The resulting ginsenoside powder derived from the supernatant
and precipitate was denoted as crude ginsenoside F1 and puriﬁed
further using a Biotage SNAP ﬂash chromatography cartridge
(180 70 4 mm; Biotage) packed with 340 g of silica resin (230e
400 mesh). The cartridge was equilibrated with chloroform, and
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sample cartridge twice. Elution was performed with 3 bed vol-
umes of chloroform and 5 bed volumes of chloroformemethanol
(85:15, v/v). Fractions were taken for every 340-mL elution (0.5 bed
volume), and the results were analyzed by TLC. The eluent was
evaporated in vacuo. The resulting powder was dissolved in 100%
methanol and analyzed via HPLC.
2.7. Analytic methods
2.7.1. TLC analysis
TLC was performed using 60F254 silica gel plates (Merck,
Darmstadt, Germany) with CHCl3eCH3OHeH2O (65:35:10, lower
phase) as the solvent. The spots on the TLC plates were identiﬁed
through comparisons with standard ginsenosides after visualiza-
tion by spraying 10% (v/v) H2SO4, followed by heating at 110C for
5 min.
2.7.2. HPLC analysis
HPLC analysis of the ginsenosides (Rb1, Rd, F1, Rh1(S), F2, Rg1,
Re, C-K, F1, and PPT) was performed using an HPLC system
(Younglin Co., Ltd, Seoul, Korea), with a quaternary pump, auto-
matic injector, single-wavelength UV detector (model 730D), and
Younglin’s AutoChro 3000 software for peak identiﬁcation and
integration. The separationwas carried out on a Prodigy ODS(2) C18
column (5 mm, 150  4.6 mm i.d.; Phenomenex, Torrance, CA, USA)
with a guard column (5 mm, 12.5  4.6 mm i.d.; Eclipse XDB C18).
The mobile phases were acetonitrile (A) and water (B). Gradient
elution started with 17% solvent A and 83% solvent B, and was then
changed as follows: A from 17% to 25%, 12e20 min; A from 25% to
32%, 20e30min; A from 32% to 55%, 30e35min; A from 55% to 60%,
35e40 min; A from 60% to 80%, 40e45 min; A from 80% to 100%,
45e50 min; A 100%, 50e54 min; A from 100% to 17%, 54.0e
54.1 min; and A 17%, 54.1e65 min. The ﬂow rate was 1.0 mL/min;
detection was performed by monitoring the absorbance at 203 nm
with an injection volume of 25 mL.
3. Results
3.1. Selection of the most effective enzyme for the production of
ginsenoside F1
We examined the generation of ginsenoside F1 from the PPTGM
reacted with several commercial enzymes for 2 d. As shown in
Table 1, ginsenoside F1 contents produced in the enzyme-treated
reaction were determined by the percentages of ginsenoside F1
among the entire measureable ginsenoside peak area using an
HPLC analysis. The commercial enzymes Novozym 960, Viscozyme,
Pectinex AFPL-4, Pectinex Ultra SP-L, and Fungamyl 800 LTable 1
Relative content of ginsenoside F1 from the PPTGM reacted with several commercial enz
Product name Declared function Origin Decla
pH
Control (PPTGM) d d d
Novozym 960 Inulinase A. niger 4.1
Viscozyme L b-Glucanase, hemicellulase Aspergillus aculeatus 4.0
Pectinex AFPL-4 Pectin lyase A. aculeatus
A. niger
4.3
Pectinex Ultra SP-L Polygalacturonase A. aculeatus 4.6
Fungamyl 800L a-Amylase Aspergillus oryzae 5.8
Cellulase KN Cellulase, naringinase A. niger 5.0
PPTGM, protopanaxatriol-type ginsenoside mixture(Novozyme) could not transform all of the ginsenosides Re and Rg1
to ginsenoside F1. However, Cellulase KN effectively transformed
ginsenosides Re and Rg1 to ginsenoside F1. As the PPTGM has
ginsenoside Re and Rg1 contents of 27.3% and 37.0%, respectively,
based on the peak area, the content of ginsenoside F1 treated with
Cellulase KN reached 57.9%, based on the peak area. The other
ginsenosides detected were a small amount of untransformed
ginsenoside Re, and protopanaxadiol-type ginsenoside F2 and
compound K derived from the ginsenosides Rb1, Rb3, and Rd. As a
result, among the six enzymes tested, ginsenoside F1 could be
produced effectively using Cellulase KN.
3.2. Biotransformation of PPT ginsenosides using Cellulase KN
For veriﬁcation of the bioconversion pathway of the two PPT
ginsenosides Re and Rg1 by Cellulase KN, TLC analyses were per-
formed at regular intervals. When Re and Rg1 (1.0 mg/mL) were
used as substrates, they were biotransformed into ginsenoside F1
within 48 h by 100 mg/mL of Cellulase KN, as shown by the Rf
values of the TLC analysis (Fig. 1). Bioconversion rate of ginsenoside
Re by Cellulase KN is much lower than that of ginsenoside Rg1.
When ginsenoside Rg1 was produced from ginsenoside Re by
Cellulase KN, it was transformed into ginsenoside F1 quickly, so it
hardly remained in the reaction mixture. Thus, it is concluded that
Cellulase KN efﬁciently hydrolyzed the rhamnose and glucose
moieties successively at the C6 position of Re, transforming it into
F1 (Fig. 2).
Cellulase KN provides the functionality of cellulase and nar-
inginase. It is generally accepted that cellulase has three main
groups of cellulolytic enzymes: cellobiohydrolase, endoglucanase,
and b-glucosidase [23]. As b-glucosidase is regarded the most
suitable enzyme for hydrolysis of the b-glucosidic linkage at C6 in
PPT-type ginsenosides, it is inferred that ginsenoside Rg1 is trans-
formed into ginsenoside F1 by the action of b-glucosidase. In
addition, naringinase is regarded as having a-L-rhamnosidase ac-
tivity against the -O-b-D-glucose (2)1)-a-L-rhamnose linkage
attached to the C6 hydroxyl group of aglycon in ginsenoside Re and
also displays higher b-glucosidase activity toward the glucosidic
linkage at C6 in ginsenoside Rg1. The above results indicated that
Cellulase KN is highly effective for biotransformation of ginseno-
sides Re and Rg1 into ginsenoside F1.
3.3. Optimization of PPTGM and enzyme concentration
Three substrate concentrations (5 mg/mL,10mg/mL, and 15mg/
mL) and two crude enzyme concentrations (50 mg/mL and 100mg/
mL) as ﬁnal concentrations were tested, in order to determine the
appropriate substrate concentration for decreasing the reactor
volume and enzyme concentration to reduce production costs. Theymes
red optimum reaction conditions Manufacturer Ginsenoside F1
content (%, area/area)
Temp. (C)
d d 0.0
45e50 Novozyme 3.4
45e50 Novozyme 35.7
45e50 Novozyme 11.0
45e50 Novozyme 7.6
45e50 Novozyme 3.8
45e50 Kyowa Chemical 57.9
A B
Fig. 1. TLC analyses of time course of ginsenosides bioconversion by Cellulase KN. (A) Transformation of ginsenoside Re. (B) Transformation of ginsenoside Rg1. Developing solvent:
CHCl3eCH3OHeH2O (65:35:10, v/v, lower phase). Lanes S represent ginsenoside standards (PPT-type ginsenosides). PPT, protopanaxatriol.
Fig. 2. Transformation pathways of ginsenosides Re and Rg1 by the commercial enzyme Cellulase KN.
Fig. 3. Effect of the concentration of the PPTGM and Cellulase KN for the production of ginsenoside F1. PPTGM, protopanaxatriol-type ginsenoside mixture.
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Fig. 4. HPLC analysis of the transformation of the PPTGM by Cellulase KN. (A) Standard
ginsenosides. (B) PPTGM as a substrate for production of F1. (C) PPTGM reacted with
Cellulase KN after 4 hours. (D) PPTGM reacted with Cellulase KN after 12 hours. (E)
PPTGM reacted with Cellulase KN after 48 hours. (F) High-purity ginsenoside F1 after
column puriﬁcation packed with silica. PPTGM, protopanaxatriol-type ginsenoside
mixture.
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analyses in six test conditions (Fig. 3). In the test conditions of a low
substrate concentration (5 mg/mL) and a high crude enzyme con-
centration (100 mg/mL), the PPTGM was completely converted to
ginsenoside F1 within 24 h; this reaction speed is 1.3 times faster
than that of the 5 mg/mL PPTGM with 50 mg/mL crude enzyme
concentration and 1.6 times faster than that of 10 mg/mL PPTGM
with 100 mg/mL crude enzyme concentration. Under the other
three reaction conditions, the conversionwas not completedwithin
48 h. These three reaction conditions were thus excluded in the
next step. Owing to the advantages of the smaller usage of enzymes
and complete conversion of Re, the conditions of 10 mg/mL sub-
strate concentration and 100 mg/mL crude enzyme concentration
were adopted for the next scaled-up biotransformation step.
3.4. Scaled-up production of ginsenoside F1 with puriﬁcation
The enzyme reaction was carried out using Cellulase KN with
PPTGM as the substrate with a concentration of 10 mg/mL, and
Cellulase KN was adjusted to 100 mg/mL as the ﬁnal concentration
in 5 L in order to produce F1. Ginsenosides Re and Rg1 in the PPTGM
were gradually changed to ginsenoside F1 with time, and 98% of
ginsenoside Rg1 and 92% of Re were converted to F1 within 48
hours. This ginsenoside bioconversion was illustrated well in the
HPLC analysis, as shown in Fig. 4AeE. This means that 11.3 g among
12.3 g Re and 9.9 g among 10.2 g of Rg1 in 50 g of PPTGM can be
changed to ginsenoside F1 to produce 17.1 g among 17.9 g,
theoretically.
In order to obtain high-purity ginsenoside F1, the enzymes, salt,
and free sugars from the reaction mixture of the 5 L reaction of
PPTGMwith Cellulase KN were removed. About half of ginsenoside
F1 precipitated to form a solid, whereas half of the remaining
quantity dissolved in the supernatant (TLC data not shown). Three
liters of a 95% ethanol solution was used, twice, to dissolve the
precipitated ginsenoside F1 thoroughly. Ginsenoside F1 in the su-
pernatant was puriﬁed using a column chromatograph packedwith
ODS (w4L of the 95% methanol eluent). Both the eluent derived
from the precipitate and the supernatant fraction were evaporated
in vacuo, yielding 26.9 g of crude ginsenoside F1. Its chromato-
graphic purity was 60.8  1.1%, as determined by HPLC. After pu-
riﬁed using a silica column, 13.0 g of high-purity ginsenoside F150 g PPTGM ± 500 g Cellulase KN
26.9 g crude F1, purity: 60.8±1.1%
13.0 g F1,  purity: 91.5±1.1%
Centrifuge
Supernatant 
Column purificaƟon 
packed with silica 
Precipitate 
Column purificaƟon 
packed with ODS
95% EtOH
EluƟon 1 EluƟon 2 
EvaporaƟon
Fig. 5. Entire process of F1 production using Cellulase KN. ODS, octadecylsilane;
PPTGM, protopanaxatriol-type ginsenoside mixture.
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The whole process is illustrated in Fig. 5.
The PPTGMwas primarily composed of ginsenosides Re and Rg1,
in which ginsenosides Rb1, Rb2, Rb3, Rd, and Rg3(S) were also
present. Among these ginsenosides, the total molar amount of Re
and Rg1 that could be biotransformed into F1 using Cellulase KN
was 24.3 mmol, which corresponds to 22.5 g of 50 g. The residue
(27.5 g) consisted of other types of ginsenosides and unknown
impurities. The molar amount of the produced high-purity ginse-
noside F1 (13.0 g) was 18.6 mmol. This indicates that the recovery
ratio through the biotransformation process using ginsenosides Re
and Rg1 of the PPTGM to F1 reached 72.7% during the entire bio-
process engineering.4. Discussion
Although F1 has antiaging, anticancer, and antioxidant effects,
the production of high-purity ginsenoside F1 is limited by eco-
nomic factors related to availability. For example, 20 mg of 98%
ginsenoside F1 costs US $163.2 in Nanjing Zelang Medical Tech-
nology Co., Ltd. Thus far, high price and the lack of a selective
technology for mass production of ginsenoside F1 have hampered
its commercial use. To achieve increased production of F1, a num-
ber of researchers have sought to biotransform major ginsenosides
Re or Rg1 into larger quantities of F1 using microorganisms and
enzymes in laboratory settings [16,17,21]. Ko et al [17] converted
ginsenoside Re to F1 by a food-grade naringinase from
P. decumbens, whereas Kim et al [21] used the recombinant b-
glucosidase from Sanguibacter keddieii. However, the aforemen-
tioned studies were tested on small scales only to conﬁrm the
bioconversion ability. Furthermore, in order to use ginsenosides
generated bymicroorganisms safely in consumables such as food, it
is desirable to use food-grade microorganisms (GRAS, generally
recognized as safe). Here, we report for the ﬁrst time that the
commercial enzyme Cellulase KN can be used to transform up to
10 mg/mL of the PPTGM to 10 gram-scale F1 within 48 h. Cellulase
KN, capable of converting ginsenosides Re and Rg1 into F1, is ex-
pected to facilitate mass production of F1 from PPT-type ginseno-
sides Re and Rg1 derived from P. quinquefolius (American ginseng)
or P. ginseng Meyer (Korean ginseng).5. Conclusion
In summary, we describe the screening of a commercial enzyme,
Cellulase KN, for the biotransformation of the major ginsenosides
Re and Rg1 into the pharmacologically active rare ginsenoside F1.
Optimized reaction conditions were obtained, and used for 10
gram-scale F1 production. The bioconversion process took place in
a 10 L jar fermenter in 100mM acetic acid buffer (pH 5.0) at 50C for
48 h, with an initial substrate concentration of 10 mg/mL. In terms
of the yield, 13.0 g of F1 with 91.5  1.1% chromatographic purity
was obtained via the biotransformation of 50 g of the PPTGM. This
is the ﬁrst report of a commercial enzyme that is capable of 10
gram-scale production of F1 through biotransformation of the
PPTGM followed by the puriﬁcation steps.Conﬂicts of interest
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